HealthEquity

The WHO's first comprehensive reports on invasive fungal diseases reveal a critical shortage of drugs and diagnostics. With only four new antifungals approved in a decade and a lack of pediatric options, the world faces a rising threat from drug-resistant fungi. The article analyzes the economic market failures, the diagnostic inequality in developing nations, and the urgent need for "Push/Pull" incentives to revitalize the R&D pipeline before resistance outpaces medical science.